SEC Form 4 · accession 0001104659-19-010802
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack A. Khattar
Officer — President, CEO · Director
Period of report
Feb 22, 2019
Accepted (ET)
Feb 26, 2019 · 7:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 453,065 | D | ||
| Common StockF1 | holding | — | — | — | 2,900 | I | By son | |
| Common Stock | holding | — | — | — | 1,085,950 | I | By the KBT Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $36.75 | Feb 22, 2019 | A | 300,000 | A | — | Feb 22, 2029 | Common Stock | 300,000 | 300,000 | D |
Explanation of responses
- F1The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.
- F2The option vests in four equal annual installments beginning on February 22, 2020.